|
Aug 7
|
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
|
Jun 26
|
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
|
|
Jun 20
|
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
|
|
May 23
|
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
|
|
May 15
|
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
|
|
Apr 24
|
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
|
|
Apr 17
|
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
|
|
Apr 1
|
Atai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
|
|
Mar 28
|
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
|
|
Mar 27
|
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
|
|
Mar 12
|
atai Life Sciences advances VLS-01 for treatment-resistant depression
|
|
Mar 4
|
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
|
|
Jan 8
|
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
|
|
Jan 5
|
Ecstasy-for-Medicine Advocate Raises $100 Million
|
|
Jan 4
|
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
|
|
Nov 14
|
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
|
|
Aug 8
|
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
|
|
May 2
|
atai Life Sciences to Participate in Upcoming May Investor Conference
|
|
Apr 28
|
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
|